Continued growth and progress for Solentim: 2019/2020 highlights
Solentim, the world leader in instruments and workflow solutions to create, isolate and characterize the highest value cells for the development of new biological medicines and therapies reports another record year for the 12 months to June 2020.
Solentim has achieved record revenue growth from instrument sales and service support, with particular strength in the USA and China markets. The company has also continued to strengthen its global partnerships over the past 12 months, including the combination of ATUM’s Leap-In Transposase® platform with Solentim’s VIPS™ single cell cloning instrument.
Solentim has strengthen its growth strategy by investing in key personnel, enhancing its capability, skill and experience to better support its global customer base. New hires include Global Marketing Manager, Global Support Manager, Director of Research and Development as well as expansion of the commercial sales and application support teams, and the appointment of Dr Mark Truesdale as CEO.
Commenting, CEO Dr Mark Truesdale said: “Solentim has had an excellent 12 months. Despite the challenges of the Coronavirus situation we have responded with creativity and resilience to continue to support our customers and grow our business. We continue to increase our investment in the business to be well placed to capitalise on market opportunities.”
Subscribe to Solentim’s newsletter to keep up to date with company and product news, and sign up to attend Solentim’s next webinar, taking place 22nd September, to be the first to hear how Solentim is establishing new standards in efficient single cell cloning of hiPSCs.